University Hospital Aachen-ko ikertzaileekin lankidetzan egindako argitalpenak (23)

2024

  1. Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

    JHEP Reports, Vol. 6, Núm. 1

  2. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut

2023

  1. Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

    Cell death & disease, Vol. 14, Núm. 8, pp. 514

  2. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

2022

  1. Activation of the unfolded protein response (Upr) is associated with cholangiocellular injury, fibrosis and carcinogenesis in an experimental model of fibropolycystic liver disease

    Cancers, Vol. 14, Núm. 1

  2. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

    Gut, Vol. 71, Núm. 8, pp. 1669-1683

  3. Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Tria

    Clinical Cancer Research, Vol. 28, Núm. 17, pp. 3890-3901

  4. Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy

    Cell death & disease, Vol. 13, Núm. 2, pp. 143

  5. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

2021

  1. Abnormal liver function test in patients infected with coronavirus (Sars-cov-2): A retrospective single-center study from spain

    Journal of Clinical Medicine, Vol. 10, Núm. 5, pp. 1-18

  2. An Experimental DUAL Model of Advanced Liver Damage

    Hepatology Communications, Vol. 5, Núm. 6, pp. 1051-1068

  3. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

  4. Fibrotic events in the progression of cholestatic liver disease

    Cells, Vol. 10, Núm. 5

  5. Serum transferrin as a biomarker of hepatocyte nuclear factor 4 alpha activity and hepatocyte function in liver diseases

    BMC Medicine, Vol. 19, Núm. 1

2020

  1. Loss of c-Jun N-terminal Kinase 1 and 2 Function in Liver Epithelial Cells Triggers Biliary Hyperproliferation Resembling Cholangiocarcinoma

    Hepatology Communications, Vol. 4, Núm. 6, pp. 834-851

  2. Serum Transferrin Is an Independent Predictor of Mortality in Severe Alcoholic Hepatitis

    American Journal of Gastroenterology, Vol. 115, Núm. 3, pp. 398-405

2019

  1. Preclinical Evaluation of a Cell-Based Gene Therapy Using the Sleeping Beauty Transposon System in Choroidal Neovascularization

    Molecular Therapy - Methods and Clinical Development, Vol. 15, pp. 403-417

2018

  1. Brain copper storage after genetic long-term correction in a mouse model of Wilson disease

    Neurology: Genetics, Vol. 4, Núm. 3

  2. Visualization of the therapeutic efficacy of a gene correction approach in Wilson's disease by laser-ablation inductively coupled mass spectrometry

    Journal of Hepatology

2017

  1. Long-Term PEDF Release in Rat Iris and Retinal Epithelial Cells after Sleeping Beauty Transposon-Mediated Gene Delivery

    Molecular Therapy - Nucleic Acids, Vol. 9, pp. 1-11